BackHemab Therapeutics Holdings Common Stock Overview
Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings Common Stock Target Price

See Hemab Therapeutics Holdings Common Stock's analyst price targets ($49) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$44.41

Average Target Price

$48.509.2% upside

10 analysts in the last 4 months

High: $64 | Low: $36

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12WedbushDavid Nierengarten$6444.1% upsideOpen
2026-08-11H.C. Wainwright$6035.1% upsideOpen
2026-07-13Jefferies$475.8% upsideOpen
2026-07-13WedbushDavid Nierengarten$5523.8% upsideOpen
2026-07-13H.C. WainwrightEmily Bodnar$5217.1% upsideOpen
2026-06-17H.C. Wainwright$409.9% downsideOpen
2026-05-26Evercore ISI$5012.6% upsideOpen
2026-05-26WedbushDavid Nierengarten$425.4% downsideOpen
2026-05-26JefferiesMaury Raycroft$3912.2% downsideOpen
2026-05-26Goldman SachsRichard Law$3618.9% downsideOpen

Hemab Therapeutics Holdings Common Stock (COAG) FAQ

As of the most recent data, COAG shows a target price of $49. Scroll down for historical charts and peer comparison views.

If Hemab Therapeutics Holdings Common Stock moved to the average analyst target of $49, shares would be roughly 9.2% higher than $44.41. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Hemab Therapeutics Holdings Common Stock's earnings trajectory.

Besides this target price page, Stockcircle has Hemab Therapeutics Holdings Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $49) with ownership activity and broader fundamentals.

Hemab Therapeutics Holdings Common Stock's target price is $49; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.